Quoin Pharmaceuticals, Ltd. (QNRX)
| Market Cap | 7.69M +49.4% |
| Revenue (ttm) | n/a |
| Net Income | -16.99M |
| EPS | -10.43 |
| Shares Out | 2.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,554,117 |
| Open | 4.270 |
| Previous Close | 3.250 |
| Day's Range | 3.630 - 4.980 |
| 52-Week Range | 3.250 - 41.800 |
| Beta | 1.68 |
| Analysts | Strong Buy |
| Price Target | 26.20 (+584.07%) |
| Earnings Date | Aug 6, 2026 |
About QNRX
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for QNRX stock is "Strong Buy." The 12-month stock price target is $26.2, which is an increase of 584.07% from the latest price.
News
Quoin Pharmaceuticals announces conditional FDA approval for Qyleki brand name
Quoin Pharmaceuticals (QNRX) announced that the FDA has conditionally approved Qyleki as the proposed brand name for QRX003, the company’s investigational product candidate for the treatment of Nether...
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA Pivotal Phase 3 Study Expected to Initiat...
Quoin Pharmaceuticals completes establishment of subsidiary in Japan
Quoin Pharmaceuticals (QNRX) announced that it has completed the establishment of a wholly-owned subsidiary in Japan as part of its strategy to directly commercialize QRX003 for the treatment of Nethe...
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
Supports Quoin's planned direct commercialization of QRX003 in Japan, one of its three core commercial territories Follows recent grant of Orphan Drug Designation to QRX003 by Japan's MHLW ASHBURN, Va...
Quoin reports positive pediatric data in Netherton Syndrome program
Quoin Pharmaceuticals (QNRX) announced a positive clinical update from its ongoing pediatric Netherton Syndrome Compassionate Use program evaluating its drug candidate, QRX003. Four of the six enrolle...
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved' or ‘Significantly Improved' from Baseline Assessment Across Key Clinical Endpoints All Six Patients Ar...
Quoin Pharmaceuticals initiated with a Buy at ThinkEquity
ThinkEquity initiated coverage of Quoin Pharmaceuticals (QNRX) with a Buy rating and $12 price target Quoin is a late-stage clinical specialty pharmaceutical company developing rare-disease dermatolog...
Quoin Pharmaceuticals granted Orphan Drug Designation for QRX003 in Japan
Quoin Pharmaceuticals (QNRX) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted Orphan Drug Designation to QRX003 for the treatment of Netherton Syndrome, a rare and…
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval- -Follows Orphan Drug Designation, Pediatric Rare Disease Designation...
Quoin Pharmaceuticals submits QRX003 IND application to FDA
Quoin Pharmaceuticals (QNRX) announced the submission of an investigational new drug, or IND, application to the FDA for QRX003 for the treatment of Peeling Skin Syndrome. Pending FDA review, Quoin…
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
-First ever IND submission for this disease, which has no current treatment or cure- -Quoin plans Phase 2 study initiation in 2H 2026- -Submission supported by positive initial clinical data from Inve...
Quoin Pharmaceuticals Earnings release: Q1 2026
Quoin Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Quoin Pharmaceuticals Quarterly report: Q1 2026
Quoin Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confir...
Quoin Pharmaceuticals initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Quoin Pharmaceuticals (QNRX) with a Buy rating and $30 price target Quoin is a late-stage clinical specialty pharmaceutical company positioned to potentially delive...
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026
ASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan...
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications.
Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin
Quoin Pharmaceuticals (QNRX) provided a clinical and regulatory update for its QRX009 topical rapamycin development programs. The company is planning to initiate several investigator-led clinical stud...
Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita...
Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global
Alliance Global raised the firm’s price target on Quoin Pharmaceuticals (QNRX) to $35 from $25 and keeps a Buy rating on the shares. The firm, which notes that its price…
Quoin Pharmaceuticals Annual report: Q4 2025
Quoin Pharmaceuticals has published its Q4 2025 annual report on March 26, 2026.
Quoin Pharmaceuticals Earnings release: Q4 2025
Quoin Pharmaceuticals released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Quoin Pharmaceuticals Ltd – ADR trading resumes
09:38 EDT Quoin Pharmaceuticals (QNRX) Ltd – ADR trading resumes
Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause
09:33 EDT Quoin Pharmaceuticals (QNRX) Ltd – ADR trading halted, volatility trading pause
Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA
Quoin Pharmaceuticals (QNRX) provided a clinical and regulatory update from its recent constructive Type C meeting with the FDA for its lead product candidate, QRX003, for the treatment of Netherton…